insights_auto
Why is 4547 up 9.85%?
Dive Deeperchevron_right
4547:TYO
Kissei Pharmaceutical Co Ltd
Â¥4,295.00
arrow_upward
+9.85%(+385.00) 1D
Nov 17, 2:19:39 PM GMT+9 · JPY
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 4547...
Open
Â¥4,040
High
Â¥4,365
Low
Â¥4,010
Mkt. cap
199.90B
Avg. vol.
82.43K
Volume
427.30K
Dividend
2.91%
Quarterly dividend
Â¥31
Ex-dividend date
Mar 30, 2027
P/E ratio
15.92
52-wk high
Â¥5,040
52-wk low
Â¥3,500
EPS
Â¥270
Shares outstanding
46.72M
No. of employees
2K
Open
Â¥4,040
High
Â¥4,365
Low
Â¥4,010
Mkt. cap
199.90B
Avg. vol.
82.43K
Volume
427.30K
Dividend
2.91%
Quarterly dividend
Â¥31
Ex-dividend date
Mar 30, 2027
P/E ratio
15.92
52-wk high
Â¥5,040
52-wk low
Â¥3,500
EPS
Â¥270
Shares outstanding
46.72M
No. of employees
2K
News stories
From web sources and news partners
TradingView
·
1 hour ago
Dow, S&P 500, Nasdaq Futures Mixed Ahead Of Much-Anticipated Nvidia Earnings, Anthropic IPO: SLS, BABA, JPM, OMER In Focus
ChartMill
·
9 hours ago
S&P 500 Top Movers: Gainers and Losers for Nov. 16, 2026
The Motley Fool
·
14 hours ago
Is an Equal-Weight S&P 500 Fund Safer Right Now Than the One You Own?
Traders Union
·
6 hours ago
Michael A. Gayed: S&P 500 fell 19.35% and high yield dropped 5.9% in Q4 2018 selloff
Profile
Kissei Pharmaceutical is a pharmaceutical company based in Matsumoto, Nagano, Japan. Products discovered or developed by Kissei include:
Difelikefalin
Fostamatinib
Linzagolix
Mitiglinide
Remogliflozin etabonate
Silodosin
Tranilast
In March 2020, Kissei and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement for CG's oncolytic immunotherapy drug CG0070. The agreement covered Japan, South Korea, Taiwan, and other Asian countries, but not China. Wikipedia
About Kissei Pharmaceutical Co Ltd
CEOMutsuo Kanzawa
Employees1.79K
FoundedAug 9, 1946
HeadquartersMatsumoto, Nagano, Japan
SectorHealth Care
IndustryPharmaceutical industry
Websitekissei.co.jp